APA (7th ed.) Citation

Felip, E., Carbone, D. P., Reck, M., Paz-Ares, L., Yuan, Y., Hu, N., . . . Lee, A. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Felip, Enriqueta, et al. Four-year Clinical Update and Treatment Switching-adjusted Outcomes with First-line Nivolumab Plus Ipilimumab with Chemotherapy for Metastatic Non-small Cell Lung Cancer in the CheckMate 9LA Randomized Trial. BMJ Publishing Group.

MLA (9th ed.) Citation

Felip, Enriqueta, et al. Four-year Clinical Update and Treatment Switching-adjusted Outcomes with First-line Nivolumab Plus Ipilimumab with Chemotherapy for Metastatic Non-small Cell Lung Cancer in the CheckMate 9LA Randomized Trial. BMJ Publishing Group.